James Allison

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10665907/publications.pdf Version: 2024-02-01



IAMES ALLISON

#	Article	IF	CITATIONS
1	B cells and tertiary lymphoid structures promote immunotherapy response. Nature, 2020, 577, 549-555.	27.8	1,421
2	High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. , 2019, 7, 351.		39
3	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2018, 19, 181-193.	10.7	233
4	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature Medicine, 2018, 24, 1649-1654.	30.7	592
5	Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. , 2017, 5, 35.		58